Top Line: Can surgery be omitted in early breast cancer patients who have a complete response to neoadjuvant therapy?
The Study: When viewed in retrospect, breast surgery (especially mastectomy and axillary dissection) can seem like overkill for patients who have a pathologic complete response to systemic therapy. Granted, at this time, we usually don’t know a patient has a pCR until after surgery. This single arm, phase 2 study asked if pCR can be accurately identified and if surgery can be selectively omitted in these select patients. The study enrolled 50 patients with cT1-2N0-1 (18% N1), HER2+ (58%; 36% HR+, 22% HR-) or triple negative breast cancer (42%). They had to have a lesion measuring <2cm after neoadjuvant therapy with a biopsy showing no invasive or in situ disease. Those with initial nodal involvement underwent a targeted axillary dissection. Of the initial 50, 34% had a radiographic complete response and 62% had a pathologic complete response by biopsy. Those with node negative disease received 40.05 Gy in 15 fractions to the breast with a 14 Gy boost. Those with nodal involvement received 50 Gy in 25 fractions to the breast and nodes. Mammograms were done every 6 months. At 5 years, the ipsilateral breast tumor recurrence was a whopping 0%. OS and DFS were 100%. Just over a third of patients (35.5%) were recommended to have breast or nodal biopsy during follow up, but all of these biopsies returned benign.
TBL: This small prospective study found very low risk of recurrence when surgery was omitted in lieu of radiation in breast cancer patients with a completed response to neoadjuvant systemic therapy. | Keurer, JAMA Oncol 2025
The Study: When viewed in retrospect, breast surgery (especially mastectomy and axillary dissection) can seem like overkill for patients who have a pathologic complete response to systemic therapy. Granted, at this time, we usually don’t know a patient has a pCR until after surgery. This single arm, phase 2 study asked if pCR can be accurately identified and if surgery can be selectively omitted in these select patients. The study enrolled 50 patients with cT1-2N0-1 (18% N1), HER2+ (58%; 36% HR+, 22% HR-) or triple negative breast cancer (42%). They had to have a lesion measuring <2cm after neoadjuvant therapy with a biopsy showing no invasive or in situ disease. Those with initial nodal involvement underwent a targeted axillary dissection. Of the initial 50, 34% had a radiographic complete response and 62% had a pathologic complete response by biopsy. Those with node negative disease received 40.05 Gy in 15 fractions to the breast with a 14 Gy boost. Those with nodal involvement received 50 Gy in 25 fractions to the breast and nodes. Mammograms were done every 6 months. At 5 years, the ipsilateral breast tumor recurrence was a whopping 0%. OS and DFS were 100%. Just over a third of patients (35.5%) were recommended to have breast or nodal biopsy during follow up, but all of these biopsies returned benign.
TBL: This small prospective study found very low risk of recurrence when surgery was omitted in lieu of radiation in breast cancer patients with a completed response to neoadjuvant systemic therapy. | Keurer, JAMA Oncol 2025

